Page last updated: 2024-12-05

molybdenum trioxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID14802
CHEBI ID30627
MeSH IDM0219320

Synonyms (68)

Synonym
ec 215-204-7
22fq3f03ys ,
unii-22fq3f03ys
molybdenum(vi) oxide
molybdenum oxide (moo3)
mo-1202t
molybdic trioxide
nsc215191
molybdic oxide
1313-27-5
molybdenum oxide (moo5)
nsc-215191
mo 1202t
molybdena
molybdenum peroxide
molybdenum trioxide
molybdic acid anhydride
wln: mo o3
molybdic anhydride
trioxomolybdenum
molybdenum(6+) oxide
CHEBI:30627
[moo3]
moo3
ccris 1163
nsc 215191
molybdenumperoxide
natural molybdite
hsdb 1661
einecs 215-204-7
molybdenum anhydride
molybdenum(vi) oxide, 99.97% trace metals basis
NCGC00260331-01
dtxcid30899
dtxsid7020899 ,
cas-1313-27-5
tox21_202785
einecs 234-321-4
AKOS015904164
molybdenum trioxide [who-dd]
molybdenum trioxide [hsdb]
molybdenum trioxide [iarc]
molybdenum trioxide [mi]
molybdenum oxide powder, 99.5% nano
JKQOBWVOAYFWKG-UHFFFAOYSA-N
molybdenum(vi)oxide
FT-0696536
molybdenum(vi) oxide, puriss. p.a., 99.5%
molybdenum(vi) oxide, nanopowder, 100 nm (tem), 99.5% trace metals basis
mfcd00003469
molybdenum(vi) oxide, acs reagent, >=99.5%
molybdenum(vi) oxide, p.a., acs reagent, 99.5%
molybdenum(vi) oxide, vetec(tm) reagent grade
molybdenum(vi) oxide, p.a., 99.0%
molybdenum(vi) oxide, reagentplus(r), >=99.5%
J-005978
Q416416
few layers mlybdenum disulfide dispersion(c: 1mg/ml, solvent: water)
few layers mos2 powder
few layers mlybdenum disulfide dispersion(c: 0.1mg/ml, solvent: ethanol)
few layers mlybdenum disulfide dispersion(c: 0.1mg/ml, solvent: water)
single layer monlybdenum disulfide nano powder
few layers mlybdenum disulfide dispersion(c: 1mg/ml, solvent: ethanol)
molybdenum oxide nanowire
molybdenum trioxide nanopowder
nitinol foil
nano molybdenum oxide powder
gadolinium (gd) sputtering targets

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Silver nanoparticles were the most toxic while molybdenum trioxide (MoO(3)) nanoparticles were the least toxic."( In vitro cytotoxicity of nanoparticles in mammalian germline stem cells.
Braydich-Stolle, L; Hofmann, MC; Hussain, S; Schlager, JJ, 2005
)
0.58

Dosage Studied

ExcerptRelevanceReference
"A mild one-pot hydrothermal route has been successfully designed to controllably prepare orthorhombic alpha-MoO3 nanobelts and monoclinic MoO2 microaxletrees respectively by adjusting the dosage of (NH4)6M07O24 x 4H2O (AHM)."( Easily controllable synthesis of alpha-MoO3 nanobelts and MoO2 microaxletrees through one-pot hydrothermal route.
Deng, C; Ge, X; Hu, H; Xu, J, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
molybdenum oxide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency4.12790.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (124)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.81)18.7374
1990's3 (2.42)18.2507
2000's20 (16.13)29.6817
2010's85 (68.55)24.3611
2020's15 (12.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.21 (24.57)
Research Supply Index4.83 (2.92)
Research Growth Index5.68 (4.65)
Search Engine Demand Index71.64 (26.88)
Search Engine Supply Index2.16 (0.95)

This Compound (45.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.61%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other122 (98.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]